Nerviano Medical sciences

SME

Nerviano Medical sciences

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Nerviano Medical sciences

Address

Nerviano, Lombardy, Italy

Contact

Online form

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Nerviano Medical sciences

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Nerviano Medical sciences last news

09/01/2024

Nerviano Medical Sciences received Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia

Nerviano Medical Sciences S.r.l. (NMS) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its next-generation FLT3 inhibitor NMS-03592088 for the treatment of Acute Myeloid Leukemia (AML). (Click the title for the complete article) L'articolo Nerviano Medical Sciences received Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia proviene da Nerviano Medical Sciences .

08/01/2024

Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery

NERVIANO Italy and PARIS France, January 8, 2024 - Iktos, a company specialized in Artificial Intelligence for new drug design, and Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, today announced a collaboration agreement in AI for unprecedented kinase project. (Click the title for the complete article) L'articolo Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery proviene da Nerviano Medical Sciences .

20/12/2023

Nerviano Medical Sciences Srl's Landmark Article in The Journal of Organic Chemistry

Nerviano Medical Sciences Srl (NMS) is pleased to announce the publication of the hot-off-the-press article "Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins" published in The Journal of Organic Chemistry  (https://doi.org/10.1021/acs.joc.3c02386) . (Click the title for the complete article) L'articolo Nerviano Medical Sciences Srl's Landmark Article in The Journal of Organic Chemistry proviene da Nerviano Medical Sciences .